Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19

HOS-215322 · Präparat HOS-155418

18  Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with (dose) Cmax, Cmin with confidence efavirenz intervals if availablea (mechanism) IMMUNOSUPPRESSANTS Immunosuppressants metabolized Interaction not studied. Decreased Dose adjustments of the by CYP3A4 (e.g. cyclosporine, exposure of the immunosuppressant immunosuppressant may be tacrolimus, sirolimus)/efavirenz may be expected (CYP3A4 required. Close monitoring of induction). These immunosuppressant immunosuppressants are not concentrations for at least 2 weeks anticipated to affect exposure of (until stable concentrations are efavirenz. reached) is recommended when starting or stopping treatment with efavirenz. NON-OPIOID ANALGESICS Metamizole/efavirenz Co-administration of efavirenz with Therefore, caution is advised metamizole, which is an inducer of when metamizole and efavirenz. metabolising enzymes including are administered concurrently; CYP2B6 and CYP3A4 may cause a clinical response and/or drug reduction in plasma concentrations of levels should be monitored as efavirenz with potential decrease in appropriate. clinical efficacy. OPIOIDS Methadone/efavirenz Methadone: Concomitant administration with (stable maintenance, 35-100 mg AUC: ↓ 52% (↓ 33 to ↓ 66) efavirenz should be avoided due once daily/600 mg once daily) Cmax: ↓ 45% (↓ 25 to ↓ 59) to the risk for QTc prolongation (CYP3A4 induction) (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) tacrolimus (HOS-085202) sirolimus (HOS-085172) cyclosporine (HOS-084512)